Boone Capital Management Invests $11.72M in Kodiak Sciences

Got story updates? Submit your updates here. ›

Boone Capital Management LLC, a hedge fund, has acquired a new position in Kodiak Sciences Inc. (NASDAQ:KOD), purchasing 715,877 shares of the biotech company's stock valued at approximately $11.72 million. Kodiak Sciences is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California that focuses on developing novel therapies for retinal diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Why it matters

This investment by Boone Capital Management represents a significant vote of confidence in Kodiak Sciences and its pipeline of retinal disease treatments. As a major new shareholder, Boone's involvement could provide additional resources and expertise to help advance Kodiak's lead candidate KSI-301, an antibody biopolymer conjugate in clinical trials for wet AMD and DME.

The details

According to Kodiak's most recent SEC filing, Boone Capital Management now owns approximately 1.35% of the company's outstanding shares. The hedge fund's position makes it the 12th largest shareholder of Kodiak Sciences. Boone's investment comes as Kodiak Sciences continues to make progress with its KSI-301 program, which has shown promising results in early-stage clinical trials for treating wet AMD and DME.

• Boone Capital Management acquired the Kodiak Sciences shares during the third quarter of 2025.

What’s next

Kodiak Sciences will continue to advance its lead candidate KSI-301 through late-stage clinical trials for wet AMD and DME, with potential regulatory filings and approvals in the coming years.